Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 30933266.
- Also identified by DOI 10.1093/cid/ciz074.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
Medical subject headings
- Antitubercular Agents
- Diarylquinolines
- Drug Resistance, Bacterial
- Extensively Drug-Resistant Tuberculosis
- Mycobacterium tuberculosis
- Nitroimidazoles
- Oxazoles